Results 1 to 10 of about 85,787 (336)
Scaling the immune incline in PDAC [PDF]
Nature Reviews Gastroenterology & Hepatology, 2021 Pancreatic ductal adenocarcinoma (PDAC) reflects the current challenge for immuno-oncology: to develop new drugs for cancers that are resistant to current immunotherapies. Here, we argue for a need to use patients to uncover new strategies that activate anti-tumour immunity.
Luis A. Rojas, Vinod P. Balachandran
openaire +3 more sources
Smart exosomes enhance PDAC targeted therapy
Journal of Controlled ReleaseExosomes continue to attract interest as a promising nanocarrier drug delivery technology. They are naturally derived nanoscale extracellular vesicles with innate properties well suited to shuttle proteins, lipids, and nucleic acids between cells.
Justin F, Creeden +10 more
openaire +3 more sources
Cancer MedicineBackground New‐Onset Diabetes Mellitus (NODM) is often an early manifestation of pancreatic cancer (Pancreatic Ductal Adenocarcinoma, PDAC). However, there is limited information about (1) the duration prior to PDAC diagnosis when the annual incidence of
Satish Munigala +8 more
doaj +3 more sources
Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma [PDF]
Iranian Journal of Medical Sciences, 2023 Background: Pancreatic cancer is a malignancy with high mortality due to the difficulties in early detection. We investigated and compared the diagnostic and prognostic performance of several blood biomarkers, including microRNA-25 (miR-25), carbohydrate
Yan Gong +5 more
doaj +1 more source
RETRACTED: Parallel Encryption With Digit Arithmetic Of Covertext Model Using Duplicated Covertext
Inspiration, 2022 Steganography is the art and science of writing hidden messages or hiding messages in such a way that, apart from the sender and the recipient, no one knows or is aware that there is a secret message (it does not appear that there is a hidden message ...
Hari Murti +3 more
doaj +1 more source
Gut, 2023 Objective Pancreatic ductal adenocarcinoma (PDAC) is characterised by an abundant desmoplastic stroma composed of cancer-associated fibroblasts (CAF) and interspersed immune cells.
F. Picard +29 more
semanticscholar +1 more source
Cell Reports, 2023 Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer that typically demonstrates resistance to chemotherapy. Tumor-associated macrophages (TAMs) are essential in tumor microenvironment (TME) regulation, including promoting chemoresistance ...
Junlei Zhang +14 more
semanticscholar +1 more source
A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment
Cell Death Discovery, 2023 Pancreatic Ductal Adenocarcinoma (PDAC) is estimated to become the second leading cause of cancer-related deaths by 2030 with mortality rates of up to 93%.
M. Geyer +5 more
semanticscholar +1 more source
Cancers, 2023 Simple Summary The aim of this review was to gather a deeper insight on the mechanisms of Pancreatic Ductal Adenocarcinoma (PDAC), with a particular focus on its biomolecular variety and underlying intracellular and intercellular mechanisms.
Leonardo Mercanti +6 more
semanticscholar +1 more source
The tumor stroma influences immune cell distribution and recruitment in a PDAC-on-a-chip model
Frontiers in Immunology, 2023 The dense tumor stroma of pancreatic ductal adenocarcinoma (PDAC) and its secreted immune active molecules provide a barrier for chemotherapy treatment as well as for immune cell infiltration to the tumor core, providing a challenge for immunotherapeutic
M. Geyer +4 more
semanticscholar +1 more source